Biora Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Athyrium Opportunities funds and related entities acquired additional convertible notes in Biora Therapeutics as payment-in-kind interest, increasing their beneficial ownership.
CEO Aditya Mohanty disposed of shares of Biora Therapeutics to cover tax withholding obligations related to vested restricted stock units.
Clarke Neumann, an officer at Biora Therapeutics, disposed of 26,629 shares to cover tax obligations related to vested restricted stock units.
Eric d'Esparbes, CFO of Biora Therapeutics, reports the disposal of 27,830 shares of common stock to cover tax obligations related to vested restricted stock units.
Athyrium Opportunities III Co-Invest 1 LP and related entities have entered into a Convertible Notes Exchange Agreement with Biora Therapeutics, Inc. to restructure their holdings of convertible notes and warrants.
Athyrium Opportunities III Acquisition LP and Athyrium Opportunities III Co-Invest 1 LP receive warrants to purchase Biora Therapeutics common stock in exchange for forbearing from exercising certain rights under convertible notes.
Athyrium Opportunities III Co-Invest 1 LP and related entities report acquisition of convertible notes in Biora Therapeutics as payment-in-kind interest.
Director Lynne Powell reports acquisition of 12,500 shares of common stock and 12,500 stock options in Biora Therapeutics.
Director Jill Ann Howe acquired 12,500 stock options and 12,500 restricted stock units in Biora Therapeutics, Inc. on June 5, 2024.
Director Brian L. Kotzin reports acquisition of Biora Therapeutics stock and options, signaling potential confidence in the company's future.
Director Jeffrey D. Alter acquired 12,500 stock options and 12,500 restricted stock units in Biora Therapeutics, Inc.